Regencell Bioscience Holdings (RGC) financial statements
Net income was -$12M.
The diluted share count rose 4846% over the period (dilution).
Income statement
Fiscal years, from Regencell Bioscience Holdings's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Research and development | $228,223 | $386,230 | $438,323 | $3M | $2M | $1M | $948,289 | $1M |
| Selling, general and admin | $162,767 | $426,141 | $943,039 | $5M | $5M | $4M | $3M | $10M |
| Operating income | -$390,990 | -$812,371 | -$1M | -$8M | -$6M | -$5M | -$4M | -$12M |
| Pre-tax income | -$390,990 | -$812,371 | -$1M | -$8M | -$6M | -$4M | -$4M | -$12M |
| Net income | -$390,990 | -$812,371 | -$1M | -$7M | -$6M | -$4M | -$4M | -$12M |
| EPS (diluted) | — | -$0.08 | -$0.13 | -$0.58 | -$1.19 | -$0.87 | -$0.72 | -$2.37 |
| Diluted shares | 10M | 10M | 10M | 13M | 494M | 494M | 494M | 495M |
Balance sheet
Fiscal years, from Regencell Bioscience Holdings's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $243,307 | $386,979 | $59,413 | $16M | $12M | $8M | $5M | $14M |
| Total current assets | — | $386,979 | $66,849 | $16M | $12M | $8M | $5M | $14M |
| Property, plant and equipment | — | $108,321 | $81,865 | $712,594 | $440,829 | $141,734 | $215,434 | $135,112 |
| Total assets | — | $514,018 | $340,134 | $18M | $13M | $8M | $6M | $15M |
| Total current liabilities | — | $3M | $4M | $577,764 | $606,914 | $193,578 | $663,673 | $1M |
| Total liabilities | — | $3M | $4M | $938,032 | $632,320 | $219,512 | $895,308 | $1M |
| Shareholders' equity | -$2M | -$3M | -$4M | $17M | $12M | $8M | $5M | $13M |
| Net debt | -$243,307 | -$386,979 | -$59,413 | -$6M | -$2M | -$3M | -$2M | -$14M |
Cash flow
Fiscal years, from Regencell Bioscience Holdings's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$390,990 | -$726,573 | -$767,311 | -$5M | -$5M | -$4M | -$3M | -$8M |
| Capital spending | — | $117,837 | — | $780,876 | $27,392 | $5,376 | $152,689 | — |
| Free cash flow | — | -$844,410 | — | -$6M | -$5M | -$4M | -$3M | — |
| Stock-based compensation | — | — | $922,623 | $3M | $922,623 | $449,311 | $244,808 | $3M |
| Net borrowing | — | $988,082 | $612,059 | -$431,969 | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for RGC.
Open RGC in InvestinglyFrom Regencell Bioscience Holdings's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.